bremelanotide vs RM-718

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: MC4R · full Obesity pipeline

bremelanotide · Vyleesi

Marketed by Cosette Pharmaceuticals and partners

Phase 2 in Obesitypeptide
Reliable signal

NCT06565611 · Phase 2 · active, not recruiting

This was a randomized, triple-blinded, placebo-controlled Phase 2 study using percent body weight change -- an objective, disease-defining measure accepted for obesity drug approval -- as its primary endpoint. According to a sourced result reported outside the registry, the bremelanotide/tirzepatide combination arm significantly outperformed placebo (4.4% vs 1.6% weight loss, p<0.0001), meeting the primary endpoint with strong statistical significance.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. The sponsor reports 113 patients enrolled and 96 randomised 3:1; the registry's 108 is its estimated enrolment.

Reported efficacy

Percent change in body weight between treatment arms (Change from the baseline (Visit 2/Day 1) to Visit 10 (Day 57)): BMT-801 study (NCT06565611): weight reduction 4.4% (bremelanotide + tirzepatide) vs 1.6% (placebo); p<0.0001. (met)

Result source: NCT06565611

RM-718

Developed by Rhythm Pharmaceuticals

Phase 1/2 in Obesitypeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: May 2027 · NCT06239116 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointbremelanotideRM-718
Body weight, % change—Not reported—Not reported
Weight loss of 5% or more—Not reported—Not reported
Weight loss of 10% or more—Not reported—Not reported
Waist circumference, change (cm)—Not reported—Not reported

Body weight, % change

bremelanotide
—Not reported
RM-718
—Not reported

Weight loss of 5% or more

bremelanotide
—Not reported
RM-718
—Not reported

Weight loss of 10% or more

bremelanotide
—Not reported
RM-718
—Not reported

Waist circumference, change (cm)

bremelanotide
—Not reported
RM-718
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

RM-718: no structured comparison results are available for Obesity.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

bremelanotide
BMT-801 study (NCT06565611): weight reduction 4.4% (bremelanotide + tirzepatide) vs 1.6% (placebo); p<0.0001. NCT06565611 · Phase 2 · design grade: strong · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: bremelanotide's landscape · RM-718's landscape